Innoviva (NASDAQ:INVA) Stock

Innoviva

Innoviva Inc is a company with a portfolio of royalties healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta and others.

Press Releases

Innoviva to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Innoviva Reports Fourth Quarter and Full Year 2024 Financial Results; Highlights Recent Company Progress

Innoviva to Participate in the Barclays 27th Annual Global Healthcare Conference

Armata Pharmaceuticals Announces $10 Million Secured Credit Agreement with Innoviva

Innoviva Reports First Quarter 2025 Financial Results; Highlights Recent Company Progress

Basilea announces commercial availability of antibiotic Zevtera® (ceftobiprole) in the United States

ZEVTERA® (ceftobiprole), an Advanced-Generation Cephalosporin Antibiotic Now Commercially Available in the U.S. to Treat Three Types of Bacterial Infections

Innoviva to Participate in Upcoming Investor Conferences

Innoviva Specialty Therapeutics Receives FDA New Drug Application Acceptance for Zoliflodacin, a First-in-Class Oral Antibiotic for Uncomplicated Gonorrhea in Adults

FDA Grants Priority Review for Zoliflodacin New Drug Application for the Treatment of Uncomplicated Gonorrhea and Assigns Target PDUFA Date of December 15, 2025

Comments

Innoviva

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL